Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib in Late Antibody-mediated Kidney Transplant Rejection
NCT01873157Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Dec 2013
- Primary completion
- Feb 2015
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in antibody mediated rejection (AMR), sponsored by Medical University of Vienna. Started Dec 2013; status: completed.
02
Drugs
bortezomib
03
Conditions
antibody mediated rejection (AMR)
Beyond the preview
Go deeper on NCT01873157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01873157.